Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitogen-activated protein kinase kinase kinase 7 (MAP3K7), commonly known as transforming growth factor-beta-activated kinase 1 (TAK1), is a serine/threonine kinase that functions as a central signaling hub in eukaryotic cells. It integrates signals from various upstream stimuli, including TGF-beta, TNF-alpha, IL-1, and Toll-like receptor ligands, to activate downstream nuclear factor-kappa B (NF-kB) and mitogen-activated protein kinase (MAPK) pathways (such as JNK and p38). Through these pathways, MAP3K7 regulates critical cellular processes including cell survival, differentiation, inflammatory responses, and death.
Dysregulation of MAP3K7 is implicated in several human pathologies; its overexpression or hyperactivation promotes tumor growth, metastasis, and chemoresistance in various cancers, while its genetic loss or mutation is linked to developmental disorders like frontometaphyseal dysplasia type 2 and cardiospondylocarpofacial syndrome. Consequently, MAP3K7 has emerged as an attractive therapeutic target. Small-molecule inhibitors, such as takinib and EYD-001, are being developed to block its kinase activity, offering potential treatments for autoimmune diseases, chronic inflammation, and treatment-refractory cancers.
Inhibition of kinase activity, typically through ATP-competitive or irreversible binding, which blocks downstream NF-kB and MAPK signaling pathways.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitogen-activated protein kinase kinase kinase 7 (MAP3K7).